19 November 2020
Kirkland Represents Investor Consortium in $4.76 Billion Take-Private of China Biologic Products
Advising firms
Deal team
16 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Gary Li Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| Xiaoxi Lin Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| Sarkis Jebejian Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| Julia Yu Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| James Hu Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| Pierre Arsenault Lead | Kirkland & Ellis | Partner | transactional | Not stated |
| Jacqueline Zheng | Kirkland & Ellis | Partner | debt finance | Not stated |
| Justin Dolling | Kirkland & Ellis | Partner | investment funds | Not stated |
| Jennifer Feng | Kirkland & Ellis | Partner | investment funds | Not stated |
| Joshua Korff | Kirkland & Ellis | Partner | capital markets | Not stated |
| Ben James | Kirkland & Ellis | Partner | capital markets | Not stated |
| Matthew Solum | Kirkland & Ellis | Partner | litigation | Not stated |
| Michael Beinus | Kirkland & Ellis | Partner | tax | Not stated |
| Devin Heckman | Kirkland & Ellis | Partner | tax | Not stated |
| Cori Lable | Kirkland & Ellis | Partner | government and internal investigations | Not stated |
| Joey Chau | Kirkland & Ellis | Partner | transactional | Not stated |
Stated terms
- Stated value
- USD 4.76bn ($4.76 billion)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- China Biologic Products Holdings, Inc. (Target)
Centurium Capital (Buy-side)
CITIC Capital (Buy-side)
Marc Chan (Buy-side)
Hillhouse Capital (Buy-side)
Temasek Holdings (Buy-side)
Joseph Chow (Buy-side)